Aptinyx

Algiax Pharmaceuticals

This clinical-stage biotechnology company develops small-molecule GABAA receptor modulators to treat patients suffering from chronic neuropathic pain and other nervous system diseases.

Neurosterix

This biopharmaceutical company develops allosteric modulator therapeutics to treat patients suffering from neurological and neuropsychiatric disorders, including schizophrenia and mood disorders.

PharmatrophiX

The company develops small-molecule therapies targeting neurotrophin receptors for patients with Alzheimer's disease and other neurodegenerative disorders.

Axonis

This biotechnology company develops oral small molecule therapies targeting the KCC2 protein to treat patients with epilepsy, chronic pain and spinal cord injuries.

Neumora Therapeutics

This biopharmaceutical company develops medicines for patients with neuropsychiatric disorders and neurodegenerative diseases.

Addex Therapeutics

This biopharmaceutical company develops oral small molecule allosteric modulators for patients with neurological disorders, including addiction, Parkinson's disease, and chronic cough.

Kynexis

This clinical-stage biotechnology company develops precision therapeutics and small-molecule inhibitors to treat cognitive impairment in patients with schizophrenia and other neurological disorders.

NMD Pharma

This company develops small molecule therapies for patients suffering from severe neuromuscular disorders to restore skeletal muscle function.